Wednesday, December 5, 2018

CCTG MA.38 - Randomized Phase II Study Comparing Two Different Schedules of Palbociclib plus Second Line Endocrine Therapy in Women with Estrogen Receptor Positive, HER2 Negative Advanced/Metastatic Breast Cancer

Time: Wednesday, December 5, 2018: 5:00 PM
Location: Stars at Night Ballroom 1 & 2
Type: Poster
Session: Spotlight Session: Developmental Therapeutics (5:00 – 7:00 PM)
Abstract: Randomized phase II study comparing two different schedules of palbociclib plus second line endocrine therapy in women with estrogen receptor positive, HER2 negative advanced/metastatic breast cancer: CCTG MA38 (NCT02630693)
Abstract #: PD1-10

SWOG S0307/CCTG MAC.9 - Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer

Time: Wednesday, December 5, 2018: 5:00 PM
Location: Hall 1
Type: Poster
Session: Poster Session 1: Treatment: Adjuvant Therapy — Other (5:00 – 7:00 PM)
Abstract: Statin use, site of recurrence, and survival among post-menopausal women taking bisphosphonates as adjuvant therapy for breast cancer (SWOG S0307)
Abstract #: P1-17-03
Authors: Kizub D, Miao J, Stopeck A, Thompson P, Paterson AH, Clemons M, Dees EC, Ingle JN, Falkson CI, Barlow W, Hortobagyi GN, Gralow JR
Thursday, December 6, 2018

CCTG MA.31 - A Randomized, Open-Label, Phase III Study of Taxane Based Chemotherapy with Lapatinib Trastuzumab as First-Line Therapy for Women with HER2/neu Positive Metastatic Breast Cancer

Time: Thursday, December 6, 2018: 7:00 AM  
Location: Stars at Night Ballroom 1 & 2  
Type: Poster  
Session: Spotlight Session: Next Steps in HER2 Targeted Therapy (7:00 – 9:00 AM)  
Abstract: Higher serum PD-L1 predicts for increased overall survival to lapatinib vs trastuzumab in the phase 3 CCTG MA.31 trial  
Abstract #: PD3-10  

GENERAL

Time: Thursday, December 6, 2018: 10:00 AM  
Location: Hall 3  
Type: Oral Session  
Session: Oral Session: General Session 3 (9:30 – 11:30 AM)  
Abstract: Effects of prolonging adjuvant aromatase inhibitor therapy beyond five years on recurrence and cause-specific mortality: An EBCTCG meta-analysis of individual patient data from 12 randomised trials including 24,912 women  
Abstract #: GS3-03  
Authors: Gray R, Early Breast Cancer Trialists' Collaborative Group  

GENERAL

Time: Thursday, December 6, 2018: 3:30 PM  
Location: Hall 3  
Type: Oral Session  
Session: Oral Session: General Session 4 (3:15 – 5:00 PM)  
Abstract: Regional lymph node irradiation in early stage breast cancer: An EBCTCG meta-analysis of 13,000 women in 14 trials  
Abstract #: GS4-02  
Link: https://www.abstracts2view.com/sabcs18/view.php?nu=SABCS18L_1158
Friday, December 7, 2018

GENERAL

Time: Friday, December 7, 2018: 7:00 AM
Location: Hall 1
Type: Poster
Session: Poster Session 4: Treatment: Adjuvant endocrine Therapy (7:30 – 9:00 AM)
Abstract: Influence of competing risks of death on the interpretation of adjuvant endocrine therapy trials for breast cancer
Abstract #: P1-14-03
Authors: Ethier J-L, Parulekar W, Shepherd L, Summers L, Strasser-Weippl K, Tu D, Amir E

ECOG PACCT-1/ MAC.12 - Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning IndividuaLized Options for Treatment: The TAILORx Trial

Time: Friday, December 7, 2018: 3:45 PM
Location: Hall 3
Type: Oral
Session: Oral Session: General Session 6 (3:15 – 5:00 PM)
Abstract: Symptoms and health-related quality of life on endocrine therapy alone (E) versus chemoendocrine therapy (C+E): TAILORx patient-reported outcomes results
Abstract #: GS6-03

Saturday, December 8, 2018

CCTG MAP.3 - A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer

Time: Saturday, December 8, 2018: 7:00 AM
Location: Hall 1
Type: Poster
Session: Poster Session 6: Epidemiology, Risk, and Prevention: Prevention — Clinical Trials (7:30 – 9:00 AM)
Abstract: Association between the UGT2B17 gene deletion, exemestane metabolites and vasomotor QOL in women participating on the MAP3 prevention trial
Abstract #: P6-13-05
Authors: Richardson H, Knight B, Chen G, Luo S, Massey T, Goss PE, Lazarus P